-
公开(公告)号：US20120189678A1
公开(公告)日：2012-07-26
申请号：US13357916
申请日：2012-01-25
Applicant: Chengwu LI , Naohisa Yoshimi , Xincheng Hu , Shuang Li , Yunhua Gao
Inventor： Chengwu LI , Naohisa Yoshimi , Xincheng Hu , Shuang Li , Yunhua Gao
IPC: A61K9/127 , A61K31/215 , A61K31/704 , A61K31/198 , A61K31/203 , A61K8/67 , A61Q19/00 , A61P17/00 , A61K8/14 , A61K8/55 , A61K8/92 , A61K8/60 , A61K31/19 , A61K31/375
CPC classification number: A61K31/19 , A61K8/14 , A61K8/44 , A61K8/4946 , A61K8/4993 , A61K8/602 , A61K8/86 , A61K9/0014 , A61K9/06 , A61K9/1271 , A61K31/198 , A61K31/203 , A61K31/375 , A61K31/704 , A61K2800/10 , A61K2800/56 , A61Q19/00
Abstract: A liposome comprising a phospholipid, a hydrophobic active comprising a carboxylate group, and a component selected from a group consisting of: a hydrophilic adjuvant comprising a positively charged group, a complex of said hydrophobic active with said hydrophilic adjuvant, and combinations thereof. An aqueous liposome dispersion comprising the liposome, and a personal care composition comprising the liposome. A process of preparing the liposome, comprising the steps of: forming a premix by dissolving a phospholipid, a hydrophobic active comprising a carboxylate group in an organic solvent; evaporating off said organic solvent from the premix to form a phospholipid film; and hydrating said lipid film with a hydration medium comprising a hydrophilic adjuvant comprising a positively charged group and homogenize the medium to form an aqueous liposome dispersion.
Abstract translation: 包含磷脂，包含羧酸酯基团的疏水性活性物质和选自以下的组分的脂质体：包含带正电基团的亲水性佐剂，所述疏水性活性物质与所述亲水性佐剂的配合物及其组合。 包含脂质体的脂质体水分散体和包含脂质体的个人护理组合物。 一种制备脂质体的方法，包括以下步骤：通过将磷脂，包含羧酸酯基团的疏水活性物质溶于有机溶剂中形成预混物; 从预混物中蒸发出所述有机溶剂以形成磷脂膜; 以及用包含带正电基团的亲水性佐剂的水合介质水合所述脂质膜，并均质培养基以形成脂质体水分散体。
-
公开(公告)号：US07491735B2
公开(公告)日：2009-02-17
申请号：US11012002
申请日：2004-12-13
Applicant: Yuanxi Zhou , Gary J. Bridger , Renato T. Skerlj , David Bogucki , Wen Yang , Elyse Bourque , Jonathan Langille , Tong-Shuang Li , Markus Metz , Maria R. Di Fluri , Siqiao Nan
Inventor： Yuanxi Zhou , Gary J. Bridger , Renato T. Skerlj , David Bogucki , Wen Yang , Elyse Bourque , Jonathan Langille , Tong-Shuang Li , Markus Metz , Maria R. Di Fluri , Siqiao Nan
IPC: A61K31/4468
CPC classification number: C07D401/14 , C07D401/12 , C07D413/14 , C07D417/14
Abstract: The present invention relates to chemokine receptor binding compounds, pharmaceutical compositions and their use. More specifically, the present invention relates to modulators of chemokine receptor activity, preferably modulators of CCR5. These compounds demonstrate protective effects against infection of target cells by a human immunodeficiency virus (HIV).
-
公开(公告)号：US20070066624A1
公开(公告)日：2007-03-22
申请号：US11505669
申请日：2006-08-16
Applicant: Yuanxi Zhou , Elyse Bourque , Yongbao Zhu , Ernest McEachern , Curtis Harwig , Renato Skerlj , Gary Bridger , Tong-Shuang Li , Markus Metz
Inventor： Yuanxi Zhou , Elyse Bourque , Yongbao Zhu , Ernest McEachern , Curtis Harwig , Renato Skerlj , Gary Bridger , Tong-Shuang Li , Markus Metz
IPC: A61K31/496 , A61K31/454 , C07D403/14 , C07D403/04
CPC classification number: C07D401/04 , C07D401/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07D471/04 , C07D493/08
Abstract: The present invention relates to chemokine receptor binding compounds, pharmaceutical compositions and their use. More specifically, the present invention relates to modulators of chemokine receptor activity, preferably modulators of CCR4 or CCR5. In one aspect, these compounds demonstrate protective effects against infection of target cells by a human immunodeficiency virus (HIV).
Abstract translation: 本发明涉及趋化因子受体结合化合物，药物组合物及其用途。 更具体地，本发明涉及趋化因子受体活性的调节剂，优选CCR4或CCR5的调节剂。 一方面，这些化合物表现出针对人类免疫缺陷病毒（HIV）感染靶细胞的保护作用。
-
公开(公告)号：US20200317636A1
公开(公告)日：2020-10-08
申请号：US16756083
申请日：2018-10-10
Applicant: Tingjunhong NI , Guangqing XU , Yuntao ZHU , Shuang LI , Jing ZHAO
Inventor： Tingjunhong NI , Guangqing XU , Yuntao ZHU , Shuang LI , Jing ZHAO
IPC: C07D401/06 , C07F9/6524
Abstract: Disclosed are a deuterated azole compound of formula (I) and a preparation method and an application of a pharmaceutically acceptable salt and prodrug of the compound. The deuterated azole compound disclosed by the invention has good antifungal activity and metabolic stability, and can be used for preparing antifungal drugs.
-
公开(公告)号：US09199949B2
公开(公告)日：2015-12-01
申请号：US14129163
申请日：2012-06-27
Applicant: Tong-Shuang Li , Ernest J. McEachern , David J. Vocadlo , Yuanxi Zhou , Harold G. Selnick
Inventor： Tong-Shuang Li , Ernest J. McEachern , David J. Vocadlo , Yuanxi Zhou , Harold G. Selnick
IPC: C07D263/58 , C07D413/04 , C07D417/04 , C07D277/60 , A61K31/423 , A61K31/428 , C07D277/82 , C12Q1/37 , C07D263/52
CPC classification number: C07D277/60 , C07D263/52 , C07D263/58 , C07D277/82 , C12Q1/37 , G01N2333/924 , G01N2500/04
Abstract: The invention provides compounds for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc.
-
Patent Agency Ranking
公开(公告)号：US20150045346A1
公开(公告)日：2015-02-12
申请号：US14129163
申请日：2012-06-27
Applicant: Tong-Shuang Li , Ernest J. McEachern , David J. Vocadlo , Yuanxi Zhou , Harold G. Selnick
Inventor： Tong-Shuang Li , Ernest J. McEachern , David J. Vocadlo , Yuanxi Zhou , Harold G. Selnick
IPC: C07D277/60 , C07D263/52
CPC classification number: C07D277/60 , C07D263/52 , C07D263/58 , C07D277/82 , C12Q1/37 , G01N2333/924 , G01N2500/04
Abstract: The invention provides compounds for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc.
Abstract translation: 本发明提供了用于选择性抑制糖苷酶，化合物前药和包含化合物的化合物或前药的药物组合物的化合物。 本发明还提供了治疗与O-GlcNAcase的缺乏或过度表达相关的疾病和障碍的方法，O-GlcNAc的积累或缺乏。
-
公开(公告)号：US20140275022A1
公开(公告)日：2014-09-18
申请号：US14129169
申请日：2012-06-27
Applicant: Tong-Shuang Li , Ernest J. Mceachern , David J. Vocadlo , Yuanxi Zhou , Yongbao Zhu , Harold G. Selnick
Inventor： Tong-Shuang Li , Ernest J. Mceachern , David J. Vocadlo , Yuanxi Zhou , Yongbao Zhu , Harold G. Selnick
IPC: C07D513/04 , C12Q1/34
CPC classification number: C07D513/04 , C07H9/06 , C12Q1/34 , C12Q1/37 , G01N2333/924 , G01N2500/04
Abstract: The invention provides compounds for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc.
-
18.发明授权Rhizopus oryzae strain, mutagenesis and screening methods thereof, and methods of fermenting to produce fumaric acid 有权米根霉菌株，其诱变和筛选方法以及发酵产生富马酸的方法公开(公告)号：US08663972B2
公开(公告)日：2014-03-04
申请号：US13992233
申请日：2011-04-16
Abstract: A rhizopus oryzae strain, mutagenesis and screening methods thereof, and methods of producing fumaric acid by fermentation. The strain is named as Rhizopus oryzae ME-F13, and deposited in China Center for Type Culture Collection with depository number CCTCC M 2010351. The strain is obtained by physically mutagenizing the original strain ME-F12 through ion injection, culturing the processed bacteria on the solid selective plate containing 2-D-deoxylucose (2-DG) and picking up 2-DG-resistant single colony. The strain is capable of simultaneously saccharifying starchy material and fermenting it to produce fumaric acid. With an improved enzymatic activity, the strain can be directly used to ferment raw starchy materials without needing pre-saccharifying.
Abstract translation: 根霉菌株，其诱变和筛选方法，以及通过发酵产生富马酸的方法。 该菌株被命名为米曲霉ME-F13，并存放于中国型号培养基中心，存放号码为CCTCC M 2010351.该菌株是通过离子注射物理诱变原始菌株ME-F12获得的， 含有2-D脱氧葡萄糖（2-DG）的固体选择性板和拾取2-DG抗性单个菌落。 该菌株能够同时糖化淀粉物质并发酵以产生富马酸。 具有改善的酶活性，该菌株可以直接用于发酵生淀粉材料，而不需要预糖化。
-
公开(公告)号：US08417596B1
公开(公告)日：2013-04-09
申请号：US11698493
申请日：2007-01-25
Applicant: Daniel P. Dunbar , Sharen M. Gerchman , Robert C. Harris , Martin Lewandowski , Shuang Li , Michael T. Maass , Clarissa D. Riggins , Lucie B. Sample , Bruce V. Wilcox
Inventor： Daniel P. Dunbar , Sharen M. Gerchman , Robert C. Harris , Martin Lewandowski , Shuang Li , Michael T. Maass , Clarissa D. Riggins , Lucie B. Sample , Bruce V. Wilcox
CPC classification number: G06Q40/123
Abstract: A graphical user interface includes a first window configured to display a first value, which is entered by a user of an income-tax preparation program, and a second value, which is computed as a function of the first value. Note that the second value is to be used in an income-tax return of the user. Furthermore, the graphical user interface allows the user to obtain an explanation of the difference between the first value and the second value.
Abstract translation: 图形用户界面包括：第一窗口，其被配置为显示由用户收入税准备程序输入的第一值，以及作为第一值的函数计算的第二值。 请注意，第二个值用于用户的纳税申报表。 此外，图形用户界面允许用户获得关于第一值和第二值之间的差的解释。
-
公开(公告)号：US20100298366A1
公开(公告)日：2010-11-25
申请号：US12851495
申请日：2010-08-05
Applicant: Yuanxi ZHOU , Elyse Bourque , Yongbao Zhu , Jonathan Langille , Markus Metz , Wen Yang , Ernest J. Mceachern , Curtis Harwig , Ian R. Baird , Tong-Shuang Li , Renato T. Skerlj
Inventor： Yuanxi ZHOU , Elyse Bourque , Yongbao Zhu , Jonathan Langille , Markus Metz , Wen Yang , Ernest J. Mceachern , Curtis Harwig , Ian R. Baird , Tong-Shuang Li , Renato T. Skerlj
IPC: A61K31/4545 , C07D413/14 , C07D413/04 , C07D401/14 , A61K31/454 , A61K31/506 , A61P31/18
CPC classification number: C07D413/14 , C07D401/12 , C07D401/14 , C07D405/14 , C07D409/14 , C07D417/14
Abstract: The present invention relates to chemokine receptor binding compounds, pharmaceutical compositions and their use. More specifically, the present invention relates to modulators of chemokine receptor activity, preferably modulators of CCR5. These compounds demonstrate protective effects against infection of target cells by a human immunodeficiency virus (HIV).
Abstract translation: 本发明涉及趋化因子受体结合化合物，药物组合物及其用途。 更具体地，本发明涉及趋化因子受体活性的调节剂，优选CCR5的调节剂。 这些化合物表现出对人体免疫缺陷病毒（HIV）感染靶细胞的保护作用。
-
-
-
-
-
-
-
-
-
Search Results
41
records
(took 0.036 seconds)
